LMBA02 Protocol for Patients With a Burkitt Lymphoma
LMBA02 Protocol for Patients With a Burkitt Lymphoma
To explore in a multicenter international prospective randomized study (phase III) whether
 rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate
 of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt
 lymphoma or ALL 3.
Inclusion Criteria:

 -  Age : 18 years or older

 -  Histologically or cytologically proven Burkitt lymphoma according to the WHO
 classification

 -  WHO performance < 3

 -  Informed consent

 Exclusion Criteria:

 -  Known HIV positive infection

 -  Positive serology for HCV and HBV (except after vaccination)

 -  Patients previously treated for lymphoma

 -  cardiac disease that contradict anthracycline chemotherapy

 -  Psychological or psychiatric condition who contradict steroids therapy

 -  Patients with serious renal failure unrelated to the lymphoma (serum creatinin level
 higher than 150 mmole/L)

 -  Cirrhosis or severe hepatic failure unrelated to the lymphoma

 -  Previous malignant disease except basal cell skin carcinoma or in situ uterine cervix
 carcinoma

 -  Any psychological, familial, sociological or geographical condition potentially
 hampering compliance with the study protocol and follow-up schedule

 -  Primary organ transplant or other immunosuppressive conditions Pregnancy